Drug class
CFTR potentiator; deuterated ivacaftor component of vanzacaftor/deutivacaftor/tezacaftor combination
Mechanism of action
Enhances the open probability of cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels at the cell surface. Deuteration modifies metabolic stability; its clinical use is as part of a fixed triple combination, not as a standalone API.
General use cases
- Component of the fixed combination ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for treatment of cystic fibrosis in eligible patients aged 6 years and older who have at least one responsive CFTR mutation, under the current product label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
